Table 1.
Clinical trials targeting survivin in cancer
| Strategy | Pathology | Phase | Clinical trials identifier |
|---|---|---|---|
| Survivin inhibitors | |||
| YM155 (survivin suppressor) together with Paclitaxel and carboplatin | Solid tumors and advanced non-small cell lung carcinoma | I/II | NCT01100931 |
| Terameprocol (EM1421), inhibitor of survivin and cdc2 (cyclin-dependent kinase-1) in continuous intravenous infusion | Refractory Solid tumors | I | NCT00664586 |
| EZN-3042, a locked nucleic acid antisense oligonucleotide | Acute Lymphoblastic Leukemia | I | NCT01186328 |
| Terameprocol (EM-1421), inhibitor of survivin and cdc2 (cyclin-dependent kinase-1) | Leukemia | I | NCT00664677 |
| EZN-3042, a survivin-targeted mRNA antagonist, alone or in combination with standard chemotherapy | Acute Lymphoblastic Leukemia | I | NCT01186328 |
| LY2181308, an antisense oligonucleotid, targeted against survivin mRNA in combination with idarubicin and cytarabine | Acute Myeloid Leukemia | II | NCT00620321 |
| Survivin-based Cellular Therapy | |||
| Dendritic cell vaccine (mRNA from PSA, PAP, survivin and hTERT) plus docetaxel or docetaxel alone | Prostate Cancer (castration resistant and metastatic) | II | NCT01446731 |
| Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion | Melanoma | I/II | NCT00961844 |
| Drug: Temozolomide | |||
| Procure®, denditric cells loaded with Survivin-peptide and Telomerase mRNA | Ovarian Cancer | I | NCT01456065 |
| Dendritic cell loaded with amplified ovarian cancer stem cell mRNA, hTERT/survivin mRNA | Ovarian Cancer | I/II | NCT01334047 |
| Cell therapy based on dendritic cells transfected with Survivin, hTERT and p53 mRNA | Metastatic breast cancer | I | NCT00978913 |
| Malignant melanoma | |||
| TAA-SPECIFIC CTLs targeting survivin, PRAME, NY-ESO-1, MAGEA4 and SSX | Solid Tumors (TACTASOM) | I | NCT02239861 |
| Treatment with autologous dendritic cells transfected with Survivin, MelanA and MAGE-A3 mRNA or loaded with MAGE-A3, MelanA and Survivin | Melanoma | I/II | NCT00074230 |
| Cell therapy with cytotoxic T lymphocytes exposed to tumor associated antigens: NY-ESO-1, MAGEA4, PRAME, Survivin and SSX. | Hodgkin or Non-Hodgkin Lymphoma | I | NCT01333046 |
| TAA-CTLs may be generated from donors or recipients and will be tested for specificity against 4 tumor antigens commonly found in hematological malignancies (WT1, PRAME, SURVIVIN, and MAGE-A3). | I | NCT02203903 | |
| Hematological | |||
| Malignancies | |||
| Dendritic cell vaccine (MUC-1 and survivin) in combination with cytokine-induced killer cells | Soft Tissue Sarcoma | I/II | NCT01898663 |
| Dendritic cell vaccine (MUC-1 and survivin) in combination with cytokine-induced killer cells | Renal Cell Carcinoma | I/II | NCT01924156 |
| Autologous dendritic cell vaccine (peptides from survivin and telomerase) | Renal Cell Carcinoma | I/II | NCT00197860 |
| Multiple antigen specific cellular therapy: autologous T cytotoxic cells induced by dendritic cells (loaded with p53, her2, survivin and a total of 17 antigens) | Hepatocellular Carcinoma | I/II | NCT02026362 |
| Vaccine therapy (p53, survivin and telomerase) with autologous dendritic cells in combination with adjuvant cytokines | Advanced Melanoma | I/II | NCT00197912 |
| Multiple tumor-associated antigen (TAA)-specific T cells (against WT1, PRAME and survivin) from donors | Acute Lymphoblastic Leukemia | I | NCT02475707 |
| Multiple tumor-associated antigen (TAA)-specific T cells (against WT1, NY-ESO-1, PRAME and survivin) from donors | Acute Lymphoblastic Leukemia/Myelodisplasic Syndrome | I | NCT02494167 |
| Multiple tumor-associated antigen (TAA)-specific cytotoxic T cells (against NY-ESO-1, IMAGEA4, PRAME, SSX and survivin) from donors | Multiple Myeloma | I | NCT02291848 |
| Survivin-vaccines | |||
| Survivin peptide vaccination in combination with sargramostin | Malignant Glioma | I | NCT01250470 |
| Vaccination with DPX-Survivin in combination with low doses of cyclophosphamide (The peptide antigens targeting survivin) | Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | I/II) | NCT01416038 |
| hTERT/survivin/CMV multipeptide vaccine | Breast Cancer | Not provided | NCT01660529 |
| Multipeptide vaccination including survivin-peptide | Multiple Myeloma | I/II | NCT00499577 |
| SurVaxM Vaccine (survivin-peptide vaccine) in combination with temozolamide | Glioblastoma | II | NCT02455557 |
| Peptide vaccine (IDO/survivine peptide) as enhancer of temozolomide chemotherapy | Metastatic Melanoma | II | NCT01543464 |
| Vaccine therapy (MART1 analog, gp100 and survivin) and GM-CSF with or without Aldesleukin | Melanoma | I | NCT00470015 |
| Vaccine therapy (survivin) in patients receiving lenalidomide | Multiple Myeloma | I | NCT02334865 |
| hTERT tumor vaccine (peptides from telomerase, survivin and cytopeptide) in combination with autologous T cell infusion | Multiple Myeloma | I/II | NCT00834665 |
| Immunotherapeutic vaccine DPX-Survivac (targeting survivin) in combination with cyclophosphamide | Diffuse Large B-Cell Lymphoma | II | NCT02323230 |
| Survivin and telomerase peptide vaccination in combination with Daclizumab and Prevnar | Advanced Breast cancer | I | NCT00573495 |
| Survivin peptide vaccination | Advanced Melanoma, pancreatic, colon and cervical cancer | I/II | NCT00108875 |